UNASSIGNED:AFIRE(利伐沙班在稳定性冠心病患者中的心房颤动和缺血性事件)试验显示,利伐沙班单药治疗与利伐沙班联合抗血小板治疗(联合治疗)相比,利伐沙班单药治疗在有效性和安全性终点方面具有非劣效性和优越性。
UASSIGNED:本研究旨在评估不同体重指数(BMI)类别患者利伐沙班单药治疗的结果。
未经评估:患者分为4组:体重不足(BMI<18.5kg/m2),正常体重(BMI18.5至<25kg/m2),超重(BMI25至<30kg/m2),和肥胖(BMI≥30kg/m2)。功效(全因死亡的复合物,心肌梗塞,不稳定型心绞痛需要血运重建,中风,或全身性栓塞)和安全性(根据国际血栓形成和止血标准定义的大出血)在不同BMI类别的利伐沙班单药治疗和联合治疗之间进行了比较。
UNASSIGNED:这项研究分析了2,054例患者,中位年龄为75.0岁,CHA2DS2-VASc评分为4。BMI类别与单药治疗的疗效(P=0.83)和安全性(P=0.07)之间没有观察到显着的相互作用。尽管单药治疗在正常体重(HR:0.64;95%CI:0.44-0.95)和超重(HR:0.25;95%CI:0.10-0.62)的疗效优于联合治疗,而在其他BMI类别中未观察到终点的显著差异.
UASSIGNED:利伐沙班单药治疗对房颤和稳定型冠状动脉疾病患者所有BMI类别的预后具有相似的影响。(稳定型冠状动脉疾病患者使用利伐沙班的心房颤动和缺血性事件[AFIRE];UMIN000016612,NCT02642419)。
UNASSIGNED: The AFIRE (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease) trial showed both noninferiority for efficacy and superiority for safety endpoints of rivaroxaban monotherapy compared with those of rivaroxaban plus antiplatelet therapy (combination therapy) in patients with atrial fibrillation and stable coronary artery disease.
UNASSIGNED: This study sought to evaluate outcomes of rivaroxaban monotherapy in those patients across body mass index (BMI) categories.
UNASSIGNED: Patients were categorized into 4 groups: underweight (BMI <18.5 kg/m2), normal weight (BMI 18.5 to <25 kg/m2), overweight (BMI 25 to <30 kg/m2), and obesity (BMI ≥30 kg/m2). Efficacy (a composite of all-cause death, myocardial infarction, unstable angina requiring revascularization, stroke, or systemic embolism) and safety (major bleeding defined according to International Society on Thrombosis and Haemostasis criteria) were compared between rivaroxaban monotherapy and combination therapy across BMI categories.
UNASSIGNED: This study analyzed 2,054 patients with a median age of 75.0 years and CHA2DS2-VASc score of 4. A significant interaction was not observed between BMI categories and effect of monotherapy for efficacy (P = 0.83) and safety (P = 0.07), although monotherapy was superior to combination therapy for efficacy in normal weight (HR: 0.64; 95% CI: 0.44-0.95) and safety in overweight (HR: 0.25; 95% CI: 0.10-0.62), whereas a significant difference in the endpoints was not observed in the other BMI categories.
UNASSIGNED: Rivaroxaban monotherapy had a similar effect on prognosis across all BMI categories in patients with atrial fibrillation and stable coronary artery disease. (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease [AFIRE]; UMIN000016612, NCT02642419).